跳转至内容
Merck
CN

T0250000

庚酸睾酮

European Pharmacopoeia (EP) Reference Standard

别名:

17β-羟基-4-雄甾烯-3-酮-17-庚酸酯, 4-雄甾烯-17β-醇-3-酮-17-庚酸酯, 睾酮-17β-庚酸酯

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H40O3
CAS号:
分子量:
400.59
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

testosterone

制造商/商品名称

EDQM

药品控制

regulated under CDSA - not available from Sigma-Aldrich Canada

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

−20°C

SMILES字符串

CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1

InChI key

VOCBWIIFXDYGNZ-IXKNJLPQSA-N

基因信息

human ... AR(367)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Testosterone enantate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

相关产品

产品编号
说明
价格

象形图

Health hazardExclamation mark

警示用语:

Danger

危险声明

危险分类

Acute Tox. 4 Oral - Carc. 1B - Repr. 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Séverine Trabado et al.
Fertility and sterility, 95(7), 2324-2329 (2011-05-04)
To evaluate the degree of E2 deficiency in male congenital hypogonadotropic hypogonadism (CHH), and its response to different hormonal treatments. Retrospective and prospective studies. Academic institution. Untreated or treated CHH, healthy men, untreated men with Klinefelter syndrome (KS). Serum sex
Carole A Samango-Sprouse et al.
American journal of medical genetics. Part A, 161A(3), 501-508 (2013-01-25)
The effects of early androgen treatment on neurodevelopmental performance in pre-pubertal boys with 47,XXY have not been well investigated. The influence of hormones on brain development in humans suggests that a positive effect on neurodevelopmental outcome in young boys with
Shane Rogerson et al.
Journal of strength and conditioning research, 21(2), 354-361 (2007-05-29)
Use of testosterone enanthate has been shown to significantly increase strength within 6-12 weeks of administration (2, 9), however, it is unclear if the ergogenic benefits are evident in less than 6 weeks. Testosterone enanthate is classified as a prohibited
Louis J G Gooren et al.
Drugs, 64(17), 1861-1891 (2004-08-27)
The major goal of androgen substitution is to replace testosterone at levels as close to physiological levels as is possible. For some androgen-dependent functions testosterone is a pro-hormone, peripherally converted to 5alpha-dihydrotestosterone (DHT) and 17beta-estradiol (E2), of which the levels
Luigi Di Luigi et al.
The journal of sexual medicine, 9(3), 873-886 (2012-02-11)
A well-tailored testosterone replacement treatment (TRT) in male hypogonadal athletes plays a pivotal role to restore physiological performances, to reduce health risks, and to guarantee the ethic of competition. Few studies evaluated individual androgens profiles during TRT in trained individuals.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门